“We are the SpaceX of the artificial heart”: Carmat launches a capital increase of 15 million euros
A l'usine de production de Bois-d'Arcy (Yvelines). DR CARMAT
Stéphane Piat, directeur général de la société, veut porter la capacité de production de l'usine de Bois-d'Arcy à 500 cœurs par an en 2024.
"We are the Space of Carmat, which is committing a capital increase of 15 million euros for its "short-term financing". "Since 2008, we have raised 500 million euros in funds", recalls the CEO, who does not fear the challenge: the price of the subscription, closed on January 25, was set at 3.99 euros per share.
Emerging from the turmoil of the first years, the company, created in 2008 from the association of Professor Alain Carpentier and the industrialist Jean-Luc Lagardère, last year reached the milestone of "50 locations in Europe",ten years after the first attempt, in 2013. Eficas, the French clinical study which includes the Montpellier University Hospital, is only one of the two ways of recruiting patients. "Forty-one hospitals from 12 countries are trained in implementation", indicates Stéphane Piat, with CE marking obtained in 2020, while the market American, which is going through a long and costly process with the FDI, is still far away: "It will be in 2027, the year of profitability"< /em>, assures Stéphane Piat.
By then, Carmat's Aeson must have proven its interest in two possible indications, "transplantation, to keep people waiting before transplantation", and "definitive therapy, or destination transplantation".Due to lack of sufficient proof of reliability and security, only the first is now retained.
Listed on the Stock Exchange
But Carmat, assures Stéphane Piat, is "many years ahead" . On other pathways that make it possible to "fight against heart failure" first, "gene therapy, stem cells, transplantation of a porcine organ". On the other players involved in the artificial heart race too: "A German company and an American company have gone bankrupt, a Swedish project is in the phase of animal experimentation, an American project is barely emerging.
From 2.8 million euros in 2023, "structuring year", the figure of& #39;business will increase, in 2024, to "14 to 20 million euros" according to forecasts. And the production capacity in the Bois-d'Arcy factory is estimated this year at 500 cores per year. In 2027, it would be a thousand.
Today, Carmat "remains a start-up", admits the CEO. A start-up with "a multidisciplinary team of around 200 highly specialized people", listed on the Euronext market  ;Growth in Paris.
Related Posts
-
Cap d'Agde: good news, Grande Conque beach should reopen in mid-July
-
“He came back with traces of beatings”: the struggle of these parents to find a reception center for their son with severe autism
-
Meningitis: compulsory vaccination will be expanded in France from the start of 2025 after an explosion of serious infections
-
Chips, shampoo, cold meats… what are the products whose prices have finally started to drop ?
About The Author
